Heron Therapeutics (HRTX) 10-K 7 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'HERON THERAPEUTICS, INC. /DE/	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	23,723,968	'
Entity Public Float	'	'	$73,726,812
Amendment Flag	'false	'	'
Entity Central Index Key	'0000818033	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$72,287	$53,506
Prepaid expenses and other current assets	638	584
Total Current Assets	72,925	54,090
Property and equipment, net	2,882	1,752
Other long-term assets	130	130
Total Assets	75,937	55,972
Current Liabilities:	'	'
Accounts payable	1,264	1,912
Accrued expenses	4,703	1,750
Convertible notes payable to related parties, net of discount	1,025	492
Total Current Liabilities	6,992	4,154
Stockholders' Equity:	'	'
Preferred stock, 2,500 shares authorized; none issued or outstanding at December 31, 2013 and 2012	0	0
Common stock, $0.01 par value, 75,000 shares authorized; 23,572 shares and 15,111 shares issued and outstanding at December 31, 2013 and 2012, respectively	237	152
Additional paid-in capital	307,578	235,253
Accumulated deficit	-238,870	-183,587
Total Stockholders' Equity	68,945	51,818
Total Liabilities and Stockholders' Equity	$75,937	$55,972

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Preferred stock, shares authorized	2,500	2,500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	75,000	75,000
Common stock, shares issued	23,572	15,111
Common stock, shares outstanding	23,572	15,111

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
REVENUE	'	'	'
Contract revenue	'	'	$646
OPERATING EXPENSES	'	'	'
Research and development	32,780	15,174	8,207
General and administrative	21,677	8,657	3,501
Total operating expenses	54,457	23,831	11,708
Operating loss	-54,457	-23,831	-11,062
OTHER INCOME (EXPENSES)	'	'	'
Interest expense, net	-826	-599	-373
Loss from continuing operations	-55,283	-24,430	-11,435
Gain (loss) from discontinued operations	'	1,082	-379
Net loss	($55,283)	($23,348)	($11,814)
Basic and diluted net loss per share:	'	'	'
Loss from continuing operations (in Dollars per share)	($3.42)	($2)	($1.90)
Net loss (in Dollars per share)	($3.42)	($1.91)	($1.96)
Weighted-average common shares used to compute basic and diluted net loss per share (in Shares)	16,163	12,223	6,013

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Common Stock Issued In Private Placement [Member]	Warrant [Member]	Total
In Thousands, except Share data
BALANCE, at Dec. 31, 2010	$20	$149,721	($148,425)	'	'	$1,316
BALANCE, (in Shares) at Dec. 31, 2010	2,007,000	'	'	'	'	'
Net loss	'	'	-11,814	'	'	-11,814
Common stock and warrants issued in private placement, net of issuance costs	80	22,692	'	'	'	22,772
Common stock and warrants issued in private placement, net of issuance costs (in Shares)	8,000,000	'	'	'	'	'
Conversion benefit included in convertible notes issued	'	1,573	'	'	'	1,573
Fair value of stock-based compensation for restricted stock awards issued/(cancelled) to directors	'	98	'	'	'	98
Fair value of stock-based compensation for restricted stock awards issued/(cancelled) to directors (in Shares)	-9,000	'	'	'	'	'
Common stock issued to employees under ESPP	'	15	'	'	'	15
Common stock issued to employees under ESPP (in Shares)	4,000	'	'	'	'	'
Stock-based compensation expense related to stock options and ESPP	'	1,762	'	'	'	1,762
Fair value of warrants issued to non-employee	'	30	'	'	'	30
BALANCE, at Dec. 31, 2011	100	175,891	-160,239	'	'	15,752
BALANCE, (in Shares) at Dec. 31, 2011	10,002,000	'	'	'	'	'
Net loss	'	'	-23,348	'	'	-23,348
Common stock issued in private placement, net of issuance costs	51	50,440	'	50,491	'	'
Common stock issued in private placement, net of issuance costs (in Shares)	5,100,000	'	'	'	'	'
Conversion benefit included in convertible notes issued	'	3,169	'	'	'	3,169
Common stock issued to employees under ESPP	'	22	'	'	'	22
Common stock issued to employees under ESPP (in Shares)	4,000	'	'	'	'	'
Warrant exercise	1	-1	'	'	'	'
Warrant exercise (in Shares)	5,000	'	'	'	'	'
Stock-based compensation expense related to stock options and ESPP	'	5,552	'	'	'	5,552
Fair value of warrants issued to non-employee	'	180	'	'	'	180
BALANCE, at Dec. 31, 2012	152	235,253	-183,587	'	'	51,818
BALANCE, (in Shares) at Dec. 31, 2012	15,111,000	'	'	'	'	'
Net loss	'	'	-55,283	'	'	-55,283
Common stock issued in private placement, net of issuance costs	77	57,725	'	57,802	'	'
Common stock issued in private placement, net of issuance costs (in Shares)	7,706,000	'	'	'	'	'
Conversion benefit included in convertible notes issued	'	291	'	'	'	291
Common stock issued to employees under ESPP	1	33	'	'	'	34
Common stock issued to employees under ESPP (in Shares)	6,000	'	'	'	'	'
Common stock issued for stock option exercises	5	2,788	'	'	'	2,793
Common stock issued for stock option exercises (in Shares)	537,000	'	'	'	'	537,029
Warrant exercise	2	598	'	'	600	'
Warrant exercise (in Shares)	212,000	'	'	'	'	'
Stock-based compensation expense related to stock options and ESPP	'	10,890	'	'	'	10,890
BALANCE, at Dec. 31, 2013	$237	$307,578	($238,870)	'	'	$68,945
BALANCE, (in Shares) at Dec. 31, 2013	23,572,000	'	'	'	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($55,283,000)	($23,348,000)	($11,814,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
(Gain) loss from discontinued operations	'	-1,082,000	379,000
Depreciation and amortization	333,000	197,000	179,000
Amortization of debt discount	533,000	389,000	103,000
Stock-based compensation expense	10,890,000	5,732,000	1,890,000
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	'	'	110,000
Prepaid expenses and other current assets	-54,000	-318,000	16,000
Other long-term assets	'	'	-77,000
Accounts payable	-426,000	984,000	467,000
Accrued expenses	3,244,000	437,000	1,298,000
Deferred revenue	'	'	-272,000
Net cash used in operating activities	-40,763,000	-17,009,000	-7,721,000
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Purchases of property and equipment	-1,685,000	-972,000	-513,000
Net cash used in investing activities	-1,685,000	-972,000	-513,000
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from sale of common stock, net of issuance costs	57,802,000	50,491,000	'
Proceeds from sale of units of common stock and warrants, net of issuance costs	'	'	22,772,000
Proceeds from convertible note financing, net of issuance costs	'	3,000,000	1,312,000
Proceeds from warrant exercises	600,000	'	'
Proceeds from the exercise of stock options	2,793,000	0	0
Proceeds from the issuance of shares under the Employee Stock Purchase Plan	34,000	22,000	15,000
Net cash provided by financing activities	61,229,000	53,513,000	24,099,000
Net increase in cash and cash equivalents	18,781,000	35,532,000	15,865,000
Cash and cash equivalents, beginning of year	53,506,000	17,974,000	2,109,000
Cash and cash equivalents, end of year	72,287,000	53,506,000	17,974,000
Supplemental Cash Flow Data:	'	'	'
Cash paid for interest	'	'	$2,000

Note_1_Business

Note 1 - Business	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	NOTE 1 BUSINESS
	Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) (the “Company,” “we,” “us” and “our”) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
	The Company’s lead product candidate, Sustol, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. Sustol contains the 5-HT3 antagonist granisetron formulated in our proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for Sustol because it is widely prescribed by physicians based on a well-established record of safety and efficacy.
	In May 2009, we filed the original New Drug Application (NDA) seeking approval for Sustol with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the Sustol NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for Sustol with the FDA. In March 2013, we received a second Complete Response Letter, which identifies several issues that preclude approval of the Sustol NDA. We believe the issues that remain are addressable, and we are working expeditiously to resubmit the Sustol NDA in the second quarter of 2014.
	We own the worldwide rights to Sustol and are in the early stage of building commercial infrastructure necessary to commercialize Sustol in the U.S. on our own.
	Additionally, we are exploring the potential use of our Biochronomer polymer with other drugs and intend to pursue the clinical development of one or more other drug candidates based on our proprietary delivery platform.
	In January 2014, we changed our name from A.P. Pharma, Inc. to Heron Therapeutics, Inc. (Name Change). The Name Change is part of our recent corporate restructuring and rebranding of the Company. We believe the Name Change will emphasize our shift from a polymer development company to a commercial phase specialty pharmaceutical company, assuming approval of Sustol.
	Effective January 13, 2014, we effected a 1-for-20 reverse split of our outstanding common stock (Reverse Stock Split). (See Notes 8 and 15).
	All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split. All stock options, convertible notes and warrants outstanding were appropriately adjusted to give effect to the Reverse Stock Split.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation and Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, accruals for research and development expenses and stock-based compensation expenses. Actual results could differ materially from those estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, stockholders’ equity or cash flows.
	We have evaluated subsequent events through the date the audited financial statements were issued (See Note 15).
	Liquidity
	We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $238.9 million as of December 31, 2013. In November 2013, we closed a common stock offering whereby we received approximately $57.8 million of proceeds, net of issuance costs. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 6). In June 2011, we entered into definitive agreements for a private placement of units, which were comprised of common stock and warrants (see Note 8). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 8). As of December 31, 2013, we had cash and cash equivalents of $72.3 million.
	We believe that our current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies or commercially launch Sustol prior to 2015, we will need to raise additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.
	Cash Equivalents
	We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We have classified all of our investments in certain debt securities as “available-for-sale.” As of December 31, 2012, our available-for-sale securities consisted of money market funds primarily containing U.S. government-backed or collateralized overnight securities with original maturities of ninety days or less. The carrying value of our money market funds is included in cash equivalents and approximates their fair value. We have no available-for-sale securities as of December 31, 2013. The Company’s bank accounts have been placed under a control agreement in accordance with the April 2011 convertible note financing (see Note 6).
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows: equipment and machinery, three to five years; furniture and fixtures, five years; and leasehold improvements, over the shorter of the respective lease terms or the respective useful lives of the leasehold improvements.
	Long-Lived Assets
	As circumstances dictate, we evaluate whether changes have occurred that would require us to consider whether long-lived assets have been impaired. Recoverability of assets to be held and used is determined by comparing the undiscounted net cash flows of long-lived assets to their respective carrying values. If such assets are considered to be impaired, the amount of impairment to be recognized is measured by comparing the projected discounted cash flows using an appropriate discount rate to the asset’s carrying value.
	Stock-Based Compensation
	We account for share-based payment arrangements in accordance with ASC 718, Compensation – Stock Compensation and ASC 505-50, Equity – Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments including stock options, restricted stock awards and stock issued under the employee stock purchase plan. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 8 for further discussion of our stock-based compensation plans.
	Warrants Issued in Connection with Equity Financings
	We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle warrants in cash.
	Revenue Recognition
	Our revenue arrangements with multiple deliverables are divided into separate units of accounting if certain criteria are met, including whether the delivered item has stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. The consideration we receive is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units. Management’s estimate of the selling price is considered when fair value is not determinable. Advance payments received in excess of amounts earned are classified as deferred revenue until earned.
	Contract Revenue
	Our licensing agreements generally provide for a non-refundable license fee. The license agreements provide for us to earn future revenue through royalty payments. These non-refundable license fees are generally initially reported as deferred revenue and recognized as revenue over an appropriate period, depending on the license. Revenue recognized from deferred license fees is classified as Contract Revenue in the accompanying statements of operations.
	Contract revenue relates to research and development arrangements that generally provide for us to invoice research and development fees based on full-time equivalent hours for each project. Revenue from these arrangements is recognized as the related development services are rendered. This revenue approximates the costs incurred.
	Clinical Trial Accruals
	Our expenses related to clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. Since the invoicing related to these services does not always coincide with our financial statement close process, we must estimate the level of services performed and fees incurred in determining the accrued clinical trial costs.
	The financial terms of these agreements are subject to negotiation and vary from contract to contract, which may result in uneven payment flows. Payments under the contracts depend on factors such as the successful enrollment of patients, achievement of certain events or the completion of portions of the clinical trial or similar conditions. Expenses related to clinical trials generally are accrued based on the level of patient enrollment and services performed by the clinical research organization or related service provider according to the protocol. We monitor patient enrollment levels and related activity to the extent possible and adjust our estimates accordingly. Historically these estimates have been reasonably accurate and no material adjustments have had to be made.
	Research and Development
	Research and development consists of costs incurred for company-sponsored and collaborative research and development expenses. These costs consist primarily of employee salaries and other personnel-related expenses, facility-related expenses, laboratory consumables, polymer development manufacturing, clinical and pre-clinical related services performed by clinical research organizations, research institutions and other outside service providers.
	Research and development expenses under collaborative agreements approximate the revenue recognized, excluding milestone and up-front payments received under such arrangements.
	Net Income (Loss) Per Share
	Basic income (loss) per share is estimated based on the weighted-average number of common shares outstanding. Diluted income (loss) per share is calculated using the weighted-average number of common shares outstanding and other dilutive securities. Dilutive securities are not included in the computation of diluted net loss per share if the inclusion of these potentially dilutive securities is anti-dilutive (see Note 9).
	Concentrations of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. We invest excess cash in a variety of high-grade short-term, interest-bearing securities. This diversification of risk is consistent with our policy to ensure safety of principal and maintain liquidity.
	Segment and Geographic Information
	Our operations are confined to a single business segment, the design and commercialization of polymer technologies for pharmaceutical and other applications.
	Comprehensive Income (Loss)
	ASC 220, Comprehensive Income, requires that an entity’s change in equity or net assets during a period from transactions and other events from non-owner sources be reported. Comprehensive loss for the periods reported was comprised solely of our net loss. The comprehensive loss for the years ended December 31, 2013, 2012 and 2011 was $55.3 million, $23.3 million and $11.8 million, respectively. There were no other changes in equity that were excluded from our net loss for all periods.
	Recent Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the fiscal year ended December 31, 2013 that we believe are of significance, or potential significance, to us.

Note_3_Fair_Value_Measurements

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	NOTE 3 FAIR VALUE MEASUREMENTS
	We follow the provisions of ASC 820-10, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and requires certain disclosures about fair value measurements. Broadly, the ASC 820-10 framework clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.
	As a basis for considering such assumptions, ASC 820-10 establishes a three tier value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1) observable inputs such as quoted prices in active markets; Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3) unobservable inputs in which there is little or no market data, which require us to develop our own assumptions. The hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	On a recurring basis, we measure our available-for-sale securities at fair value. We used quoted prices in active markets (Level 1) to measure our cash equivalents at fair value on a recurring basis in our balance sheet at December 31, 2012. Cash equivalents consist of highly rated money market funds with maturities of ninety days or less and purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of these funds, we consider the values of all cash equivalents as Level 1 inputs. We did not hold any cash equivalents at December 31, 2013.
	The carrying amounts reported in the balance sheets for accounts payable and accrued expenses approximate fair value because of the short-term nature of these items.

Note_4_Property_and_Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 4 PROPERTY AND EQUIPMENT
	Property and equipment consist of the following (in thousands):
	December 31,	2013			2012
	Leasehold improvements	$	1,360		$	1,346
	Furniture and equipment		5,795			4,036
	Construction-in-progress		-			777
	Total property and equipment		7,155			6,159
	Accumulated depreciation		(4,273	)		(4,407	)
	Property and equipment, net	$	2,882		$	1,752
	Depreciation expense amounted to $333,000, $197,000 and $179,000 for the years ended December 31, 2013, 2012 and 2011, respectively. At December 31, 2012, construction-in-progress related to equipment purchases not placed in service.

Note_5_Accrued_Expenses

Note 5 - Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 5 ACCRUED EXPENSES
	Accrued expenses consist of the following (in thousands):
	December 31,	2013		2012
	Research and development costs	$	1,795	$	651
	Accrued compensation		2,566		401
	Other		342		698
	Total	$	4,703	$	1,750

Note_6_Convertible_Notes_to_Re

Note 6 - Convertible Notes to Related Parties	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 6 CONVERTIBLE NOTES PAYABLE TO RELATED PARTIES
	In April 2011, we entered into a Securities Purchase Agreement (Purchase Agreement) with certain institutional investors (Purchasers), including a fund affiliated with Kevin C. Tang, who is the Chairman of our Board of Directors, for a private placement of up to $4.5 million in Senior Secured Convertible Notes due 2021 (Notes). The Purchase Agreement provided for the Purchasers to purchase $1.5 million aggregate principal amount of Notes at the initial closing. Pursuant to the Purchase Agreement, the Purchasers had the option to purchase an additional $3.0 million aggregate principal amount of Notes at any time until May 2, 2013 (Purchase Option). The Notes are convertible into shares of the Company’s common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes (Conversion Shares).
	The cash received from the initial closing of the Note financing, which resulted in the issuance of $1.5 million aggregate principal amount of Notes, was approximately $1.3 million, net of issuance costs. In May 2012, the Purchasers exercised their Purchase Option in full, and we received $3.0 million of cash through the issuance of the remaining $3.0 million aggregate principal amount of Notes. As a result of the exercise of the Purchase Option, the Purchasers have purchased the full amount of Notes that the Company was obligated to sell under the Purchase Agreement.
	The Notes are secured by substantially all of the assets of the Company, including placing our bank accounts under a control agreement. The Notes initially bore interest at 20% per annum, payable quarterly in cash or in additional principal amount of Notes at the election of the Purchasers. In June 2011, the Notes were amended to reduce the interest rate to 6% per annum effective July 1, 2011. The Notes mature on May 2, 2021; however, the holders of the Notes may require prepayment of the Notes at any time, at each holder’s option.
	There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of the Company’s outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to the Company, which will not be effective until 61 days after delivery of the notice.
	As of December 31, 2013, the Company was in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require the Company to redeem all or a portion of their Notes.
	Pursuant to the Purchase Agreement, the Company filed a registration statement on Form S-1, registering for resale 3.5 million shares (as adjusted for the reverse stock split) underlying the Notes. The registration statement was declared effective on July 29, 2011. The Purchasers have agreed to waive their right to require the Company to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.
	The Notes contain an embedded conversion feature that was in-the-money on both issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates and the Company began amortizing the resultant debt discount over the respective 10-year term of the Notes. During the year ended December 31, 2013, accrued interest of approximately $291,000 was paid-in-kind and rolled into the Note principal balance, which resulted in an additional debt discount of approximately $291,000. For the years ended December 31, 2013, 2012 and 2011, interest expense relating to the stated rate was approximately $295,000, $216,000 and $97,000, respectively, and interest expense relating to the amortization of the debt discount was approximately $533,000, $389,000 and $103,000, respectively.
	As of December 31, 2013, the carrying value of the Notes was approximately $1,025,000, which is comprised of the $5,033,000 principal amount of the Notes outstanding, less debt discount of $4,008,000. If the $5.0 million principal amount of Notes is converted, the Company would issue 6.0 million shares of its common stock. Accrued interest on the principal balance was approximately $75,000 at December 31, 2013.

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 7 COMMITMENTS AND CONTINGENCIES
	Our lease for office, warehouse and laboratory space in Redwood City, California expires in 2016. Our Stamford, Connecticut office space is being leased on a month-to-month basis. Our office space in San Diego, California is being leased for an initial term that expires in December 2014. We also lease certain office equipment under operating lease arrangements. Our future minimum lease payments under these non-cancelable operating leases for facilities and equipment are as follows (in thousands):
	For the Years Ended December 31,	Minimum
		Payments
	2014	$	922
	2015		779
	2016		722
	Total	$	2,423
	Total rental expense for facilities and equipment was $967,000, $580,000 and $591,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	As permitted under Delaware law and in accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving at our request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, we have a director or officer insurance policy that limits our exposure and may enable us to recover a portion of any future payments. We believe the fair value of these indemnification agreements is minimal. Accordingly, we have not recorded any liabilities for these agreements as of December 31, 2013.
	In the normal course of business, we provide indemnifications of varying scope under our agreements with other companies, typically our clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, we generally indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with use or testing of our products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to our products. The term of these indemnification agreements is generally perpetual. The potential future payments we could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. We also maintain various liability insurance policies that limit our exposure. As a result, we believe the fair value of these indemnification agreements is minimal. Accordingly, we have not recorded any liabilities for these agreements as of December 31, 2013.

Note_8_Stockholders_Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 8 STOCKHOLDERS’ EQUITY
	Amendments to Certificate of Incorporation
	Reverse Stock Split
	Effective January 13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc. and to effect a 1-for-20 reverse split of our outstanding common stock. The Name Change and Reverse Stock Split were approved by our stockholders on September 19, 2013. As a result of the Reverse Stock Split, the total authorized shares of common stock were reduced from 1,500,000,000 to 75,000,000 shares (See Note 15).
	2009 Private Placement
	In October 2009, in a private placement, we sold 397,727 shares of our common stock at $17.60 per share and warrants to purchase 198,864 shares of our common stock, exercisable through January 7, 2015, at an exercise price of $17.60 per share (2009 Private Placement). The purchasers paid $2.50 per underlying share for the warrants. Additionally, the purchasers had the right to purchase up to an additional 258,264 shares at $19.40 per share prior to May 14, 2010 and paid $2.50 per underlying share for the right to purchase such additional shares. These rights expired unexercised on May 14, 2010. Total proceeds from the 2009 Private Placement were approximately $7.9 million, net of issuance costs. We filed a registration statement on Form S-3 covering 376,631 shares on November 6, 2009, which was declared effective by the SEC on November 17, 2009. On June 30, 2010, we filed a registration statement on Form S-3 covering the remaining 21,096 shares and the 198,864 shares of our common stock underlying the warrants, which was declared effective by the SEC on July 8, 2010. If we fail to keep any registration statements continuously effective, we may be obligated to pay to the holders of the shares and warrants liquidated damages in the amount of 1% per month of the purchase price for the shares and warrants, up to a maximum cap of 8% of such purchase price.
	2011 Private Placement
	In June 2011, we entered into a Securities Purchase Agreement with certain purchasers (Securities Purchase Agreement), pursuant to which we agreed to sell 8.0 million shares of our common stock (Shares) and warrants to purchase 4.0 million shares of our common stock (Warrants) with an exercise price of $3.60 per share (2011 Private Placement), for an aggregate price of $24.0 million. The 2011 Private Placement closed on July 1, 2011. For each share purchased, the investors received one Warrant to purchase 0.5 shares of common stock (together with a Share, a Unit), at a purchase price of $3.00 per Unit. The Warrants were immediately exercisable and expire on the fifth anniversary of the closing date of July 1, 2011. The Warrants may be exercised for cash only or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the Warrants, by surrender of such Warrant, or a portion of such Warrant, by way of cashless exercise. There is no right to exercise the Warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the Warrants can amend or waive the foregoing limitation by written notice to the Company, with such waiver taking effect only upon the expiration of a 61-day notice period.
	Under the terms of the Securities Purchase Agreement, on July 29, 2011, the Company filed a registration statement with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants (the Warrant Shares, and collectively with the Shares, the Registrable Securities). The registration statement was declared effective on August 4, 2011. The Company is obligated to maintain the effectiveness of the registration statement with respect to an investor’s Registrable Securities until the investor is able to sell the Registrable Securities without limitation or restriction under Rule 144. There is currently only one investor who is an affiliate of the Company and is therefore not able to sell the Registrable Securities without limitation under Rule 144, and that investor has agreed to waive its right to require the Company to maintain the effectiveness of the registration statement until it provides notice otherwise. If the Company fails to keep the registration statement continuously effective for a designated time (with limited exceptions) during the period the Company is obligated to maintain the registration statement, the Company may be obligated to pay to the holders of the Registrable Securities liquidated damages in an amount equal to 1.0% per month of such holder’s pro rata interest in the total purchase price of the Private Placement, capped at a total penalty of 6.0%.
	The Company received total proceeds of $22.8 million from the 2011 Private Placement, which was net of issuance costs of approximately $1.2 million. During the year 2013, the Company received $0.6 million for an exercise of a Warrant.
	2012 Private Placement
	In July 2012, the Company entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell 5.1 million shares of its common stock (2012 Shares) at a purchase price of $10.50 per share of common stock, for an aggregate price of approximately $53.6 million (2012 Private Placement). The Company received total proceeds of $50.5 million from the 2012 Private Placement, which was net of issuance costs of approximately $3.1 million.
	In connection with entering into the securities purchase agreement, the Company also entered into a registration rights agreement. On August 24, 2012, the Company filed a registration statement with the SEC to register the 2012 Shares for resale. The registration statement was declared effective on September 6, 2012. If the Company fails to keep the registration statement continuously effective for a designated time (with limited exceptions), the Company may be obligated to pay to each holder of the 2012 Shares an amount equal to 1.5% per month of the aggregate purchase price of the unregistered 2012 Shares held by such holder, capped at a total penalty of 9.0%.
	2013 Common Stock Offering
	On November 20, 2013, the Company entered into an underwriting agreement (Underwriting Agreement) with Jefferies LLC, as representative of the several underwriters (Underwriters), pursuant to which we agreed to issue and sell an aggregate of 7,500,000 shares of our common stock to the Underwriters (Offering). Under the terms of the Underwriting Agreement, we granted the Underwriters an option for 30 days to purchase up to an additional 1,125,000 shares of our common stock.
	The shares in the Offering were sold at a public offering price of $8.00 per share. The public offering closed on November 25, 2013. We received net proceeds of $56.3 million, after deducting the Underwriters’ discounts and commissions and offering expenses payable by us. On December 5, 2013, the Underwriters exercised their option to purchase 206,500 of the 1,125,000 additional shares of common stock. We received net proceeds of $1.5 million from issuance of these additional shares.
	The Offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-190550), which was previously filed with the Securities and Exchange Commission (SEC) and was declared effective, and a prospectus supplement filed with the SEC. The Offering was not registered under any state blue sky laws and was limited to “Qualified Institutional Buyers” (as defined in Rule 144A under the Securities Act of 1933, as amended) and certain other institutional and accredited investors, as permitted under applicable law. In the Underwriting Agreement, we agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities.
	Stock-Based Compensation Plans
	We have two types of stock-based compensation plans, which consist of an employee stock purchase plan and three stock option plans.
	In 1997, our stockholders approved our 1997 Employee Stock Purchase Plan (the Purchase Plan). In December 2007, May 2009 and June 2011, our stockholders authorized increases in the number of shares reserved for issuance under the Purchase Plan by 5,000, 10,000 and 25,000 shares, respectively, for a total of 50,000 shares reserved at December 31, 2013. Under the terms of the Purchase Plan, employees can elect to have up to a maximum of 10% of their base earnings withheld to purchase our common stock. The purchase price of the stock is 85% of the lower of the closing prices for our common stock on: (i) the first trading day in the enrollment period, as defined in the Purchase Plan, in which the purchase is made, or (ii) the purchase date. The length of the enrollment period may not exceed a maximum of six months. Our compensation committee modified the Purchase Plan such that beginning in May 2008, the length of all offering periods was decreased from 24 months to six months. Enrollment dates are the first business day of May and November and the first enrollment date was April 30, 1997. Approximately 9% of eligible employees participated in the Purchase Plan in 2013. Under the Purchase Plan, we issued 5,634, 4,274 and 3,899 shares in 2013, 2012 and 2011, respectively. The weighted-average fair value per share of purchase rights granted during 2013, 2012 and 2011 was $7.23, $5.20 and $4.00, respectively. The weighted-average exercise price per share of the purchase rights exercised during 2013, 2012 and 2011 was $6.12, $5.20 and $4.00, respectively. We had 16,651, 22,285 and 26,559 shares reserved for issuance under the Purchase Plan at December 31, 2013, 2012 and 2011, respectively.
	We currently have one stock option plan from which we can grant options and restricted stock awards to employees, officers, directors and consultants. In December 2007, the stockholders approved our 2007 Equity Incentive Plan (the 2007 Plan). In May 2010 and June 2011, our stockholders approved amendments to our 2007 Equity Incentive Plan to increase the maximum number of shares of common stock available for grant by 100,000 and 4,500,000 shares of common stock, respectively, resulting in an aggregate of 4,750,000 shares of common stock authorized for issuance pursuant to awards granted under our 2007 Equity Incentive Plan. We have also granted stock options and restricted stock awards under the 2002 Stock Incentive Plan (the 2002 Plan) and the Non-Qualified Stock Plan (the NQ Plan) in prior years. We were authorized to issue up to 21,250 shares under the 2002 Plan, which includes an increase of 5,000 shares which were approved by stockholders in May 2006, and 103,125 shares under the NQ Plan, a plan that had not undergone stockholder approval and could only be utilized to grant stock options and restricted stock awards as inducements to attract new employees, to which 50,000 shares were added by the Board of Directors in September 2007, and an additional 50,000 shares were added in July 2008. The remaining shares available in the NQ Plan and 2002 Plan expired in October 2010 and February 2012, respectively. In 2013 and 2012, we granted options to certain employees outside of our approved stock option plan. The options to purchase our common stock are granted with an exercise price which equals fair market value of the underlying common stock on the grant dates and expire no later than ten years from the date of grant. The options are exercisable in accordance with vesting schedules that generally provide for them to be fully vested and exercisable four years after the date of grant. Any shares that are issuable upon exercise of options granted that expire or become unexercisable for any reason without having been exercised in full are available for future grant and issuance under the same stock option plan.
	As discussed in Note 2, we record stock-based compensation expense based on the fair value of stock options and purchase rights issued to employees in conjunction with our stock option plans or the Purchase Plan on the grant date or purchase date. We also record compensation expense for warrants and stock options issued to non-employees and restricted stock awards to employees and directors.
	The fair value of each employee and director grant of options to purchase common stock and purchase rights under the Purchase Plan is estimated on the date of the grant using the Black-Scholes option-pricing model assuming no dividends and the following weighted-average assumptions:
	For the Years Ended December 31,		2013			2012				2011
	Expected term (years):
	Stock options			6			5.51				5
	Employee Stock Purchase Plan			0.49			0.49				0.5
	Risk-free interest rate:
	Stock options			1.5	%		0.8	%			1.6	%
	Employee Stock Purchase Plan			0.8	%		0.2	%			0.8	%
	Volatility:
	Stock options			105	%		106	%			106	%
	Employee Stock Purchase Plan			212	%		0.8	%			142	%
	The expected term is based on historical data. The expected term for the Purchase Plan is based on the weighted-average purchase period of the Purchase Plan. The risk-free interest rate is based on the U.S. treasury rate over the expected term of the award. The expected volatility is based on our historical stock prices, and the estimated forfeiture rate of the options is based on historical data.
	The Black-Scholes option valuation model requires the input of highly subjective assumptions, including the expected life of the award and stock price volatility. The assumptions listed above represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if other assumptions had been used, our recorded stock-based compensation expense could have been materially different.
	Stock-based compensation expense recorded for awards granted under the stock option plans and the Purchase Plan, net of estimated forfeitures, was as follows (in thousands, except per share amounts):
	For the Years Ended December 31,		2013			2012				2011
	Research and development		$	2,562		$	1,585			$	819
	General and adminstrative			8,328			4,147				1,071
	Total		$	10,890		$	5,732			$	1,890
	Impact on basic and diluted net loss per common share		$	0.67		$	0.47			$	0.31
	We recorded additional stock-based compensation expense in 2013 and 2012 as a result of accelerated vesting of stock options in connection with the resignation of our former chief executive officer and two directors, respectively. No tax benefit was recognized related to stock-based compensation expense since we have incurred operating losses and we have established a full valuation allowance to offset all the potential tax benefits associated with our deferred tax assets.
	The following table summarizes option activity for the years ended December 31, 2013, 2012 and 2011:
			2013													2012						2011
			Shares			Weighted-				Weighted-			Aggregate			Shares			Weighted-			Shares			Weighted-
						Average				Average			Intrinsic						Average						Average
						Exercise				Remaining			Value as of						Exercise						Exercise
						Price				Contractual			December						Price						Price
										Term (Years)			31, 2013
	Outstanding at beginning of year			4,323,874		$	8.46										2,505,283		$	6.13			160,833		$	29.83
	Granted			4,256,971			8.08										1,874,246			11.61			2,403,495			5.19
	Exercised			(537,029	)		5.2										-			-			-			-
	Expired or Forfeited			(1,688,135	)		9.45										(55,655	)		9.56			(59,045	)		32.53
	Outstanding at end of year			6,355,681			8.22				8.14		$	10,704,578			4,323,874			8.46			2,505,283			6.13
	Options exercisable at year end			1,770,597			8.67				5.12		$	4,607,452			1,142,099			7.98			337,002			10.68
	Options vested or expected to vest			6,292,296			8.22				8.13		$	10,614,670			4,283,344			8.45			2,471,725			6.14
	Shares available for future grant at year end			1,797,694													1,018,766						2,213,155
	Weighted-average fair value of stock options granted during the year		$				8.08												$	11.61					$	5.19
	As of December 31, 2013, there was approximately $39.1 million of total unrecognized compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average period of 2.55 years. Cash received from option exercises for the years ended December 31, 2013, 2012 and 2011 was $2,793,000, $0 and $0, respectively. The total intrinsic value of options exercised in the year ended December 31, 2013, 2012 and 2011 was $1.7 million, $0 and $0, respectively.
	The following table summarizes information about stock options outstanding at December 31, 2013:
							OPTIONS OUTSTANDING										OPTIONS EXERCISABLE
		Range of Exercise Prices					Number Outstanding				Weighted-Average Remaining Contractual Life (Years)			Weighted-Average Exercise Price			Number Exercisable			Weighted-Average Exercise Price
			$3.80	-	$3.80			5,000				7.99		$	3.8			2,708		$	3.8
		$5.20	-	$5.20			1,072,887				4.02			5.2			997,934			5.2
		$6.40	-	$7.00			386,613				8.6			6.85			80,210			6.66
		$7.20	-	$7.20			3,190,240				9.34			7.2			41,012			7.2
		$7.40	-	$10.60			852,372				9.38			9.89			105,881			10.57
		$11.00	-	$15.00			730,285				7.54			13.15			499,642			12.79
		$15.40	-	$130.40			117,598				6.44			24.14			42,524			39.54
		$139.20	-	$139.20			125				1.08			139.2			125			139.2
		$196.00	-	$196.00			436				0.04			196			436			196
		$235.12	-	$235.12			125				0.4			235.12			125			235.12
		$3.80	-	$235.12			6,355,681				8.14		$	8.22			1,770,597		$	8.67
As of December 31, 2013, there were no unvested restricted stock awards granted to employees and directors. The compensation cost that has been expensed in the statements of operations for the restricted stock awards issued to employees and directors was $0 for 2013 and 2012 and, $98,000 for 2011, respectively.
The following table summarizes information about the Company’s warrants outstanding at December 31, 2013:
		Number of Shares Exercisable			Exercise Price			Expiration Date
Issued to private placement investors in October 2009			198,864		$	17.6		1/7/15
Issued to private placement investors in July 2011			3,750,000		$	3.6		7/1/16
Other			20,000		$	13.8		8/1/15
Total warrants outstanding at December 31, 2013			3,968,864		$	4.35*
* Average exercise price
Common Stock Reserved for Future Issuance
As of December 31, 2013, the Company had reserved shares of common stock for future issuance as follows:
		No. of Shares
Issuance upon exercise of outstanding stock options			6,355,681
Issuance of future grants under stock option plans			1,797,694
Issuance of future grants under employee stock purchase plan			16,651
Issuance of common stock related to convertible notes*			9,884,342
Issuance upon exercise of warrants			3,968,864
Total			22,023,232
*Assumes all interest payments are paid-in-kind through the maturity date.

Note_9_Net_Loss_Per_Share

Note 9 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 9 NET LOSS PER SHARE
	Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the applicable period. Diluted net loss per share excludes the effect of outstanding potentially dilutive securities because they are anti-dilutive. The following table shows the outstanding potentially dilutive options, warrants and convertible notes as of December 31, 2013, 2012 and 2011 (in thousands):
	For the Years Ended December 31,	2013		2012		2011
	Number of options outstanding		6,356		4,324		2,505
	Number of warrants outstanding		3,969		4,219		4,206
	Common stock related to convertible notes outstanding		6,291		5,927		1,967

Note_10_Discontinued_Operation

Note 10 - Discontinued Operations	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	'
	NOTE 10 DISCONTINUED OPERATIONS
	Cosmeceutical and Toiletry Business
	On July 25, 2000, we completed the sale of certain technology rights for our cosmeceutical and toiletry business to RP Scherer Corporation (RP Scherer), a subsidiary of Cardinal Health, Inc. Under the terms of the agreement, we guaranteed a minimum gross profit percentage on RP Scherer's combined sales of products to Ortho Dermatologics (Ortho) and Dermik Laboratories, Inc. (Dermik) (Gross Profit Guaranty), both of which were acquired by Valeant Pharmaceuticals in July 2011. The Gross Profit Guaranty expense totaled $944,000 for the first seven guaranty years. Effective March 2007, in conjunction with a sale of assets by RP Scherer’s successor company to an Amcol International subsidiary (Amcol), a new agreement was signed between us and Amcol to provide continuity of product supply to Ortho and Dermik. We had previously recorded a liability of $1.1 million related to the amount that Amcol asserted was due under the Gross Profit Guaranty. In February 2013, an arbitrator ruled that no additional amounts were owed. This event qualified as an adjusting event under ASC 855, Subsequent Event, and in light of the arbitrator’s decision in February 2013, which was final and binding, we reversed this accrual as of December 31, 2012.
	The cosmeceutical and toiletry business is reported as discontinued operations for all periods presented in the accompanying Statements of Operations. Gain (loss) from discontinued operations represents primarily the gain (loss) attributable to changes in estimates of our cosmeceutical and toiletry business that was sold to RP Scherer on July 25, 2000, as follows (in thousands):
	For the years ended December 31,	2013		2012		2011
	Cosmeceutical and Toiletry Business:
	Change in estimates for guarantees	$	-	$	1,082	$	(379	)
	There was no revenue relating to discontinued operations for the years ended December 31, 2013, 2012 and 2011.
	Basic and diluted income (loss) per common share from discontinued operations was $0, $0.09 and ($0.06) for the years ended December 31, 2013, 2012 and 2011, respectively.

Note_11_Defined_Contribution_P

Note 11 - Defined Contribution Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	NOTE 11 DEFINED CONTRIBUTION PLAN
	We have a defined contribution plan (401k) covering substantially all of our employees. In the past three calendar years, we made matching cash contributions equal to 50% of each participant’s contribution during the plan year up to a maximum amount equal to the lesser of 3% of each participant’s annual compensation or $7,650, $7,500 and $7,350 for the years 2013, 2012 and 2011, respectively. Such amounts were recorded as expense in the corresponding years. We may also contribute additional discretionary amounts to the defined contribution plan as we may determine. For the years ended December 31, 2013, 2012 and 2011, we contributed to the plan approximately $134,000, $71,000 and $46,000, respectively. No discretionary contributions have been made to the plan since its inception.

Note_12_Income_Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 12 INCOME TAXES
	There is no provision recorded for the fiscal years ended 2013, 2012 and 2011 because we have incurred operating losses.
	Deferred income taxes reflect the net tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows (in thousands):
	December 31,	2013			2012			2011
	Deferred Tax Assets:
	Net operating loss carryforwards	$	31,834		$	13,900		$	6,700
	Research credits		4,792			2,300			2,100
	Stock compensation expense		4,124			2,600			600
	Other		487			400			900
	Total deferred tax assets		41,237			19,200			10,300
	Valuation allowance		(41,237	)		(19,200	)		(10,300	)
	Net deferred tax assets	$	-		$	-		$	-
	Realization of our deferred tax assets is dependent upon our future taxable income, if any, the timing and amount of which are uncertain. Accordingly, our deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $22.0 million and $8.9 million during 2013 and 2012, respectively.
	As of December 31, 2013, we had federal and California net operating loss carryforwards of $80.1 million and $79.1 million, respectively, and federal and California research and development tax credit carryforwards of $2.2 million and $3.9 million, respectively. Of the carryforwards, federal and California net operating loss carryforwards of $75.0 million and $74.0 million, respectively, are subject to annual limitations and will be available from 2014 through 2031, as a result of federal ownership change limitations. The remaining federal and state net operating losses carryforwards expire beginning in 2018 for federal and 2014 for state, through 2033, if not utilized. The federal research credits expire beginning in 2022 and the state research credits have no expiration date.
	Federal and state laws limit the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. We conducted an analysis of our stock ownership under Internal Revenue Code Section 382 and have reported our deferred tax assets related to net operating loss and research credit carryforwards after recognizing change of control limitations in 2007, 2011 and 2013. The limitation of our federal and state carryforwards associated with previous net operating loss and research credit carryforwards, and the associated reduction in our deferred tax assets, was offset by a reduction in our valuation allowance. Utilization of our remaining net operating loss and research and development credit carryforwards may still be subject to substantial annual limitations due to ownership change limitations after December 31, 2013. Such an annual limitation could result in the expiration of the net operating loss and research and development credit carryforwards available as of December 31, 2013 before utilization.
	The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (34% in 2013, 2012 and 2011) to income taxes as follows (in thousands):
	December 31,	2013			2012			2011
	Tax benefit computed at 34%	$	(18,796	)	$	(7,937	)	$	(4,017	)
	Stock compensation expense		513			176			148
	Other		300			210			70
	NOL not benefitted		17,983			7,551			3,799
	Tax Provision (Benefit)	$	-		$	-		$	-
	We follow the provisions of ASC 740-10-50, Accounting for Uncertainty in Income Tax Provisions. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):
	December 31,	2013			2012			2011
	Unrecognized tax benefit:
	At the beginning of the period	$	120		$	120		$	120
	Gross increases – tax positions in the current period		-			-			-
	Gross decreases – tax positions in the current period		-			-			-
	At the end of the period	$	120		$	120		$	120
	The unrecognized tax benefit, if recognized in full, would result in adjustments to deferred taxes and the related valuation allowance. We do not currently anticipate any significant changes to the unrecognized tax benefits in 2014. Our policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of tax expense. To date, we have not used the unrecognized tax benefits to reduce any of our past tax obligations. As a result, we had no accrual for the payment of interest and penalties related to the unrecognized tax benefits. As of December 31, 2013, our tax returns were subject to future examination in the U.S. federal and state tax jurisdictions for the tax years 1997 through 2013, due to net operating losses and research credits that are being carried forward.

Note_13_Significant_Agreements

Note 13 - Significant Agreements	12 Months Ended
	Dec. 31, 2013
Table Text Block [Abstract]	'
Research and Development Arrangement, Contract to Perform for Others [Table Text Block]	'
	NOTE 13 SIGNIFICANT AGREEMENTS
	Merial Limited
	In September 2009, we entered into a world-wide license and development agreement with Merial Limited (Merial), a world leading animal health company, for a long acting pain management product for companion animals. We received a nonrefundable upfront license fee and performed reimbursable development services. In May 2011, we received notice of termination from Merial. We recognized $0.6 million in revenue related to development services to Merial for the year ended 2011.

Note_14_Quarterly_Results_of_O

Note 14 - Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	NOTE 14 QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)
	The following table presents summarized unaudited results of operations for each of our quarters in the years ended December 31, 2013 and 2012.
	Quarterly Results of Operations
	(in thousands, except per share data)
	(unaudited)
	Year Ended December 31, 2013	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	Total revenue	$	-		$	-		$	-		$	-
	Operating expenses		12,752			15,209			12,664			13,832
	Interest and other expense, net		(201	)		(204	)		(209	)		(212	)
	Net loss		(12,953	)		(15,413	)		(12,873	)		(14,044	)
	Basic and diluted net loss per share:
	Net loss	$	(0.85	)	$	(1.01	)	$	(0.84	)	$	(0.75	)
	Year Ended December 31, 2012	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	Total revenue	$	-		$	-		$	-		$	-
	Operating expenses		4,769			4,380			6,054			8,628
	Interest and other expense, net		(61	)		(146	)		(195	)		(197	)
	Loss from continuing operations		(4,830	)		(4,526	)		(6,249	)		(8,825	)
	Discontinued operations		(91	)		(43	)		128			1,088
	Net loss		(4,921	)		(4,569	)		(6,121	)		(7,737	)
	Basic and diluted net loss per share:
	Loss from continuing operations	$	(0.48	)	$	(0.45	)	$	(0.46	)	$	(0.58	)
	Net loss		(0.49	)		(0.46	)		(0.45	)		(0.51	)

Note_15_Subsequent_Event

Note 15 - Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 15 SUBSEQUENT EVENT
	Reverse Stock Split
	Effective January 13, 2014, we amended our Certificate of Incorporation to change our name to Heron Therapeutics, Inc., and to effect a 1-for-20 reverse split of our outstanding common stock. The Name Change and Reverse Stock Split were approved by our stockholders on September 19, 2013. As a result of the Reverse Stock Split, the total authorized shares of common stock were reduced from 1,500,000,000 to 75,000,000 shares.
	All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split. All stock options, convertible notes and warrants outstanding were ratably adjusted to give effect to the Reverse Stock Split.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Use of Estimates [Policy Text Block]	'
	Basis of Presentation and Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates were made relating to useful lives of fixed assets, valuation allowances, impairment of assets, accruals for research and development expenses and stock-based compensation expenses. Actual results could differ materially from those estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, stockholders’ equity or cash flows.
	We have evaluated subsequent events through the date the audited financial statements were issued (See Note 15).
Liquidity Disclosure [Policy Text Block]	'
	Liquidity
	We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $238.9 million as of December 31, 2013. In November 2013, we closed a common stock offering whereby we received approximately $57.8 million of proceeds, net of issuance costs. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 6). In June 2011, we entered into definitive agreements for a private placement of units, which were comprised of common stock and warrants (see Note 8). The unit financing, which closed in July 2011, provided us with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, we closed a common stock financing whereby we received approximately $50.5 million of proceeds, net of issuance costs (see Note 8). As of December 31, 2013, we had cash and cash equivalents of $72.3 million.
	We believe that our current working capital is sufficient to fund essential operations into 2015; provided, however, that if we pursue additional clinical studies or commercially launch Sustol prior to 2015, we will need to raise additional capital. We may require additional capital to fund our development pipeline programs. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash Equivalents
	We consider all highly liquid investments with a maturity from the date of purchase of less than three months to be cash equivalents. We have classified all of our investments in certain debt securities as “available-for-sale.” As of December 31, 2012, our available-for-sale securities consisted of money market funds primarily containing U.S. government-backed or collateralized overnight securities with original maturities of ninety days or less. The carrying value of our money market funds is included in cash equivalents and approximates their fair value. We have no available-for-sale securities as of December 31, 2013. The Company’s bank accounts have been placed under a control agreement in accordance with the April 2011 convertible note financing (see Note 6).
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows: equipment and machinery, three to five years; furniture and fixtures, five years; and leasehold improvements, over the shorter of the respective lease terms or the respective useful lives of the leasehold improvements.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	'
	Long-Lived Assets
	As circumstances dictate, we evaluate whether changes have occurred that would require us to consider whether long-lived assets have been impaired. Recoverability of assets to be held and used is determined by comparing the undiscounted net cash flows of long-lived assets to their respective carrying values. If such assets are considered to be impaired, the amount of impairment to be recognized is measured by comparing the projected discounted cash flows using an appropriate discount rate to the asset’s carrying value.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	We account for share-based payment arrangements in accordance with ASC 718, Compensation – Stock Compensation and ASC 505-50, Equity – Equity Based Payments to Non-Employees, which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments including stock options, restricted stock awards and stock issued under the employee stock purchase plan. These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 8 for further discussion of our stock-based compensation plans.
Warrants Issued In Equity Financings [Policy Text Block]	'
	Warrants Issued in Connection with Equity Financings
	We generally account for warrants issued in connection with equity financings as a component of equity, unless there is a deemed possibility that we may have to settle warrants in cash.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Our revenue arrangements with multiple deliverables are divided into separate units of accounting if certain criteria are met, including whether the delivered item has stand-alone value to the customer and whether there is objective and reliable evidence of the fair value of the undelivered items. The consideration we receive is allocated among the separate units based on their respective fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units. Management’s estimate of the selling price is considered when fair value is not determinable. Advance payments received in excess of amounts earned are classified as deferred revenue until earned.
Contract Revenue [Policy Text Block]	'
	Contract Revenue
	Our licensing agreements generally provide for a non-refundable license fee. The license agreements provide for us to earn future revenue through royalty payments. These non-refundable license fees are generally initially reported as deferred revenue and recognized as revenue over an appropriate period, depending on the license. Revenue recognized from deferred license fees is classified as Contract Revenue in the accompanying statements of operations.
	Contract revenue relates to research and development arrangements that generally provide for us to invoice research and development fees based on full-time equivalent hours for each project. Revenue from these arrangements is recognized as the related development services are rendered. This revenue approximates the costs incurred.
Clinical Trial Accruals [Policy Text Block]	'
	Clinical Trial Accruals
	Our expenses related to clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. Since the invoicing related to these services does not always coincide with our financial statement close process, we must estimate the level of services performed and fees incurred in determining the accrued clinical trial costs.
	The financial terms of these agreements are subject to negotiation and vary from contract to contract, which may result in uneven payment flows. Payments under the contracts depend on factors such as the successful enrollment of patients, achievement of certain events or the completion of portions of the clinical trial or similar conditions. Expenses related to clinical trials generally are accrued based on the level of patient enrollment and services performed by the clinical research organization or related service provider according to the protocol. We monitor patient enrollment levels and related activity to the extent possible and adjust our estimates accordingly. Historically these estimates have been reasonably accurate and no material adjustments have had to be made.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development consists of costs incurred for company-sponsored and collaborative research and development expenses. These costs consist primarily of employee salaries and other personnel-related expenses, facility-related expenses, laboratory consumables, polymer development manufacturing, clinical and pre-clinical related services performed by clinical research organizations, research institutions and other outside service providers.
	Research and development expenses under collaborative agreements approximate the revenue recognized, excluding milestone and up-front payments received under such arrangements.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Income (Loss) Per Share
	Basic income (loss) per share is estimated based on the weighted-average number of common shares outstanding. Diluted income (loss) per share is calculated using the weighted-average number of common shares outstanding and other dilutive securities. Dilutive securities are not included in the computation of diluted net loss per share if the inclusion of these potentially dilutive securities is anti-dilutive (see Note 9).
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentrations of Credit Risk
	Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. We invest excess cash in a variety of high-grade short-term, interest-bearing securities. This diversification of risk is consistent with our policy to ensure safety of principal and maintain liquidity.
Segment Reporting, Policy [Policy Text Block]	'
	Segment and Geographic Information
	Our operations are confined to a single business segment, the design and commercialization of polymer technologies for pharmaceutical and other applications.
Comprehensive Income, Policy [Policy Text Block]	'
	Comprehensive Income (Loss)
	ASC 220, Comprehensive Income, requires that an entity’s change in equity or net assets during a period from transactions and other events from non-owner sources be reported. Comprehensive loss for the periods reported was comprised solely of our net loss. The comprehensive loss for the years ended December 31, 2013, 2012 and 2011 was $55.3 million, $23.3 million and $11.8 million, respectively. There were no other changes in equity that were excluded from our net loss for all periods.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the fiscal year ended December 31, 2013 that we believe are of significance, or potential significance, to us.

Note_4_Property_and_Equipment_

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	December 31,	2013			2012
	Leasehold improvements	$	1,360		$	1,346
	Furniture and equipment		5,795			4,036
	Construction-in-progress		-			777
	Total property and equipment		7,155			6,159
	Accumulated depreciation		(4,273	)		(4,407	)
	Property and equipment, net	$	2,882		$	1,752

Note_5_Accrued_Expenses_Tables

Note 5 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	December 31,	2013		2012
	Research and development costs	$	1,795	$	651
	Accrued compensation		2,566		401
	Other		342		698
	Total	$	4,703	$	1,750

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	For the Years Ended December 31,	Minimum
		Payments
	2014	$	922
	2015		779
	2016		722
	Total	$	2,423

Note_8_Stockholders_Equity_Tab

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	For the Years Ended December 31,		2013			2012				2011
	Expected term (years):
	Stock options			6			5.51				5
	Employee Stock Purchase Plan			0.49			0.49				0.5
	Risk-free interest rate:
	Stock options			1.5	%		0.8	%			1.6	%
	Employee Stock Purchase Plan			0.8	%		0.2	%			0.8	%
	Volatility:
	Stock options			105	%		106	%			106	%
	Employee Stock Purchase Plan			212	%		0.8	%			142	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	For the Years Ended December 31,		2013			2012				2011
	Research and development		$	2,562		$	1,585			$	819
	General and adminstrative			8,328			4,147				1,071
	Total		$	10,890		$	5,732			$	1,890
	Impact on basic and diluted net loss per common share		$	0.67		$	0.47			$	0.31
Schedule of Share-based Compensation, Activity [Table Text Block]	'
			2013													2012						2011
			Shares			Weighted-				Weighted-			Aggregate			Shares			Weighted-			Shares			Weighted-
						Average				Average			Intrinsic						Average						Average
						Exercise				Remaining			Value as of						Exercise						Exercise
						Price				Contractual			December						Price						Price
										Term (Years)			31, 2013
	Outstanding at beginning of year			4,323,874		$	8.46										2,505,283		$	6.13			160,833		$	29.83
	Granted			4,256,971			8.08										1,874,246			11.61			2,403,495			5.19
	Exercised			(537,029	)		5.2										-			-			-			-
	Expired or Forfeited			(1,688,135	)		9.45										(55,655	)		9.56			(59,045	)		32.53
	Outstanding at end of year			6,355,681			8.22				8.14		$	10,704,578			4,323,874			8.46			2,505,283			6.13
	Options exercisable at year end			1,770,597			8.67				5.12		$	4,607,452			1,142,099			7.98			337,002			10.68
	Options vested or expected to vest			6,292,296			8.22				8.13		$	10,614,670			4,283,344			8.45			2,471,725			6.14
	Shares available for future grant at year end			1,797,694													1,018,766						2,213,155
	Weighted-average fair value of stock options granted during the year		$				8.08												$	11.61					$	5.19
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	'
							OPTIONS OUTSTANDING										OPTIONS EXERCISABLE
		Range of Exercise Prices					Number Outstanding				Weighted-Average Remaining Contractual Life (Years)			Weighted-Average Exercise Price			Number Exercisable			Weighted-Average Exercise Price
			$3.80	-	$3.80			5,000				7.99		$	3.8			2,708		$	3.8
			$5.20	-	$5.20			1,072,887				4.02			5.2			997,934			5.2
			$6.40	-	$7.00			386,613				8.6			6.85			80,210			6.66
			$7.20	-	$7.20			3,190,240				9.34			7.2			41,012			7.2
			$7.40	-	$10.60			852,372				9.38			9.89			105,881			10.57
			$11.00	-	$15.00			730,285				7.54			13.15			499,642			12.79
			$15.40	-	$130.40			117,598				6.44			24.14			42,524			39.54
			$139.20	-	$139.20			125				1.08			139.2			125			139.2
			$196.00	-	$196.00			436				0.04			196			436			196
			$235.12	-	$235.12			125				0.4			235.12			125			235.12
			$3.80	-	$235.12			6,355,681				8.14		$	8.22			1,770,597		$	8.67
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
			Number of Shares Exercisable			Exercise Price			Expiration Date
	Issued to private placement investors in October 2009			198,864		$	17.6		1/7/15
	Issued to private placement investors in July 2011			3,750,000		$	3.6		7/1/16
	Other			20,000		$	13.8		8/1/15
	Total warrants outstanding at December 31, 2013			3,968,864		$	4.35*
Common Stock Reserved For Future Issuance [Table Text Block]	'
			No. of Shares
	Issuance upon exercise of outstanding stock options			6,355,681
	Issuance of future grants under stock option plans			1,797,694
	Issuance of future grants under employee stock purchase plan			16,651
	Issuance of common stock related to convertible notes*			9,884,342
	Issuance upon exercise of warrants			3,968,864
	Total			22,023,232

Note_9_Net_Loss_Per_Share_Tabl

Note 9 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	For the Years Ended December 31,	2013		2012		2011
	Number of options outstanding		6,356		4,324		2,505
	Number of warrants outstanding		3,969		4,219		4,206
	Common stock related to convertible notes outstanding		6,291		5,927		1,967

Note_10_Discontinued_Operation1

Note 10 - Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Income (Loss) from Discontinued Operations [Table Text Block]	'
	For the years ended December 31,	2013		2012		2011
	Cosmeceutical and Toiletry Business:
	Change in estimates for guarantees	$	-	$	1,082	$	(379	)

Note_12_Income_Taxes_Tables

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	December 31,	2013			2012			2011
	Deferred Tax Assets:
	Net operating loss carryforwards	$	31,834		$	13,900		$	6,700
	Research credits		4,792			2,300			2,100
	Stock compensation expense		4,124			2,600			600
	Other		487			400			900
	Total deferred tax assets		41,237			19,200			10,300
	Valuation allowance		(41,237	)		(19,200	)		(10,300	)
	Net deferred tax assets	$	-		$	-		$	-
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	December 31,	2013			2012			2011
	Tax benefit computed at 34%	$	(18,796	)	$	(7,937	)	$	(4,017	)
	Stock compensation expense		513			176			148
	Other		300			210			70
	NOL not benefitted		17,983			7,551			3,799
	Tax Provision (Benefit)	$	-		$	-		$	-
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
	December 31,	2013			2012			2011
	Unrecognized tax benefit:
	At the beginning of the period	$	120		$	120		$	120
	Gross increases – tax positions in the current period		-			-			-
	Gross decreases – tax positions in the current period		-			-			-
	At the end of the period	$	120		$	120		$	120

Note_14_Quarterly_Results_of_O1

Note 14 - Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013													Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]	'													'
Schedule of Quarterly Financial Information [Table Text Block]	'													'
	Year Ended December 31, 2013	First Quarter			Second Quarter			Third Quarter			Fourth Quarter			Year Ended December 31, 2012	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	Total revenue	$	-		$	-		$	-		$	-		Total revenue	$	-		$	-		$	-		$	-
	Operating expenses		12,752			15,209			12,664			13,832		Operating expenses		4,769			4,380			6,054			8,628
	Interest and other expense, net		(201	)		(204	)		(209	)		(212	)	Interest and other expense, net		(61	)		(146	)		(195	)		(197	)
	Net loss		(12,953	)		(15,413	)		(12,873	)		(14,044	)	Loss from continuing operations		(4,830	)		(4,526	)		(6,249	)		(8,825	)
	Basic and diluted net loss per share:													Discontinued operations		(91	)		(43	)		128			1,088
	Net loss	$	(0.85	)	$	(1.01	)	$	(0.84	)	$	(0.75	)	Net loss		(4,921	)		(4,569	)		(6,121	)		(7,737	)
														Basic and diluted net loss per share:
														Loss from continuing operations	$	(0.48	)	$	(0.45	)	$	(0.46	)	$	(0.58	)
														Net loss		(0.49	)		(0.46	)		(0.45	)		(0.51	)

Note_1_Business_Details

Note 1 - Business (Details) (Subsequent Event [Member], Common Stock [Member])	0 Months Ended
	Jan. 13, 2014
Subsequent Event [Member] | Common Stock [Member]	'
Note 1 - Business (Details) [Line Items]	'
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	1 Months Ended						12 Months Ended
	Nov. 20, 2013	Nov. 30, 2013	Jul. 31, 2012	31-May-12	Jul. 31, 2011	Apr. 30, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Retained Earnings (Accumulated Deficit)	'	'	'	'	'	'	($238,870,000)	($183,587,000)	'	'
Proceeds from Issuance of Common Stock	56,300,000	57,800,000	'	'	'	'	57,802,000	50,491,000	'	'
Convertible Debt Issuable In Connection With Private Placement1	'	'	'	'	'	4,500,000	'	'	'	'
Proceeds from Convertible Debt	'	'	'	3,000,000	'	1,300,000	'	3,000,000	1,312,000	'
Proceeds From Sale Of Units Of Common Stock And Warrants Net	'	'	'	'	22,800,000	'	'	'	'	'
Proceeds from Issuance of Private Placement	'	'	50,500,000	'	'	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	'	'	'	'	'	'	72,287,000	53,506,000	17,974,000	2,109,000
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'	'	'	($55,300,000)	($23,300,000)	($11,800,000)	'
Machinery and Equipment [Member] | Minimum [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Estimated Useful Lives	'	'	'	'	'	'	'three	'	'	'
Machinery and Equipment [Member] | Maximum [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Estimated Useful Lives	'	'	'	'	'	'	'five	'	'	'
Furniture and Fixtures [Member]	'	'	'	'	'	'	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Estimated Useful Lives	'	'	'	'	'	'	'five	'	'	'

Note_4_Property_and_Equipment_1

Note 4 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Abstract]	'	'	'
Depreciation	$333,000	$197,000	$179,000

Note_4_Property_and_Equipment_2

Note 4 - Property and Equipment (Details) - Property and equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$7,155	$6,159
Accumulated depreciation	-4,273	-4,407
Property and equipment, net	2,882	1,752
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,360	1,346
Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	5,795	4,036
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	'	$777

Note_5_Accrued_Expenses_Detail

Note 5 - Accrued Expenses (Details) - Accrued expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued expenses [Abstract]	'	'
Research and development costs	$1,795	$651
Accrued compensation	2,566	401
Other	342	698
Total	$4,703	$1,750

Note_6_Convertible_Notes_to_Re1

Note 6 - Convertible Notes to Related Parties (Details) (USD $)

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Jul. 29, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 30, 2011

Apr. 30, 2011

Apr. 30, 2011

31-May-12

Jun. 30, 2011

Dec. 31, 2013

Apr. 30, 2011

Apr. 30, 2011

Apr. 30, 2011

Apr. 30, 2011

Initial Closing Amount [Member]

Purchase Option [Member]

Notes Payable, Other Payables [Member]

Notes Payable, Other Payables [Member]

Notes Payable, Other Payables [Member]

Notes Payable, Other Payables [Member]

Common Stock [Member]

Senior Notes [Member]

Principal Amount [Member]

Note 6 - Convertible Notes to Related Parties (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debt Issuable In Connection With Private Placement1

'

'

'

'

$4,500,000

'

'

'

'

'

$4,500,000

'

'

'

Notes Authorized Under Private Placement Initial Closing

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

Purchase Option Under Private Placement

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

Debt Instrument Conversion Ratio, Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

1,250

'

'

Debt Instrument Conversion Ratio, Multiple of Principal

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

5,033,000

'

'

1,500,000

'

Proceeds from Debt, Net of Issuance Costs

'

'

'

'

'

'

'

3,000,000

'

'

'

'

1,300,000

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

6.00%

'

20.00%

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

2-May-21

'

'

'

'

'

Beneficial Ownership After Conversion

'

'

'

'

'

'

'

'

9.99%

'

'

'

'

'

Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes

'

'

'

'

'

'

'

'

'61 days

'

'

'

'

'

Common Shares Registered For Resale In Connection With Convertible Notes (in Shares)

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Paid-in-Kind Interest

'

'

'

'

'

'

'

'

'

291,000

'

'

'

'

Interest Expense, Debt, Excluding Amortization

'

295,000

216,000

97,000

'

'

'

'

'

'

'

'

'

'

Amortization of Debt Discount (Premium)

'

533,000

389,000

103,000

'

'

'

'

'

'

'

'

'

'

Carrying Value of Notes Outstanding

'

1,025,000

492,000

'

'

'

'

'

'

1,025,000

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

4,008,000

'

'

'

'

Debt Instrument, Convertible, Number of Equity Instruments

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

Interest Payable, Current

'

'

'

'

'

'

'

'

'

$75,000

'

'

'

'

Note_7_Commitments_and_Conting2

Note 7 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'
Operating Leases, Rent Expense, Net	$967,000	$580,000	$591,000

Note_7_Commitments_and_Conting3

Note 7 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Minimum Lease Payments [Abstract]	'
2014	$922
2015	779
2016	722
Total	$2,423

Note_8_Stockholders_Equity_Det

Note 8 - Stockholders' Equity (Details) (USD $)

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

28 Months Ended

15 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Nov. 20, 2013

Nov. 30, 2013

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 13, 2014

Jan. 13, 2014

Jan. 13, 2014

Oct. 31, 2009

Nov. 20, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2009

Nov. 06, 2009

Jun. 30, 2010

Oct. 31, 2009

Jun. 30, 2011

Jul. 30, 2012

Dec. 05, 2013

Nov. 20, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2009

Dec. 31, 2013

Jun. 30, 2010

Oct. 31, 2009

Jun. 30, 2011

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 30, 2012

Jun. 30, 2011

31-May-09

Dec. 31, 2007

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2011

31-May-10

Dec. 31, 2013

31-May-06

Oct. 31, 2010

Jul. 31, 2008

Sep. 30, 2007

Dec. 31, 2013

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Maximum Additional Purchase [Member]

Sold At Public Offering [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Private Placement 2009 [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Private Placement 2009 [Member]

Private Placement 2009 [Member]

Private Placement 2011 [Member]

Private Placement 2011 [Member]

Private Placement 2011 [Member]

Private Placement 2012 [Member]

Private Placement 2012 [Member]

Employee Stock Purchase Plan 1997 [Member]

Employee Stock Purchase Plan 1997 [Member]

Employee Stock Purchase Plan 1997 [Member]

Employee Stock Purchase Plan 1997 [Member]

Employee Stock Purchase Plan 1997 [Member]

Employee Stock Purchase Plan 1997 [Member]

Equity Incentive Plan 2007 [Member]

Equity Incentive Plan 2007 [Member]

Equity Incentive Plan 2007 [Member]

Stock Incentive Plan 2002 [Member]

Stock Incentive Plan 2002 [Member]

Non-qualified Plan [Member]

Non-qualified Plan [Member]

Non-qualified Plan [Member]

Scenario, Previously Reported [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Form S-3 Registration Statement [Member]

Form S-3 Registration Statement [Member]

Private Placement 2009 [Member]

Private Placement 2011 [Member]

Private Placement 2012 [Member]

Jefferies LLC [Member]

Jefferies LLC [Member]

Private Placement 2009 [Member]

Private Placement 2009 [Member]

Private Placement 2009 [Member]

Private Placement 2009 [Member]

Note 8 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity Note, Stock Split, Conversion Ratio

'

'

'

'

'

'

'

20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

'

75,000,000

75,000,000

'

1,500,000,000

'

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

397,727

8,000,000

5,100,000

206,500

7,500,000

212,000

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

$8

'

'

'

'

'

'

$17.60

'

'

'

'

'

'

'

$2.50

'

'

'

'

'

'

'

$10.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

3,968,864

'

'

'

'

'

258,264

'

'

'

'

'

'

'

198,864

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)

'

'

'

$4.35

[1]

'

'

'

'

'

$19.40

'

'

'

'

'

'

'

$17.60

$3.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

$4.35

[1]

'

'

'

'

'

$19.40

'

'

'

'

'

'

'

$17.60

$3.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement (in Dollars)

'

'

$50,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,900,000

'

'

$22,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Previously Issued During Prior Period, Shares Registered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

376,631

21,096

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Underlying Securities Registered (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

198,864

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective Rate Of Liquidated Damages

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

1.00%

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement Capped Penatly

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

6.00%

9.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(in Dollars)

'

'

'

'

'

22,772,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000

'

'

'

'

24,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Available Per Warrant Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Limitation On Exercisable Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Stock Issuance Costs (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises (in Dollars)

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53,600,000

'

'

2,000

1,000

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock (in Dollars)

56,300,000

57,800,000

'

57,802,000

50,491,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

50,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

22,023,232

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,651

22,285

26,559

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

10,000

5,000

'

'

'

4,500,000

100,000

'

5,000

'

50,000

50,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

4,750,000

'

21,250

'

'

103,125

Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Earnings Withheld to Purchase Common Stock,Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Discount on Stock Purchase Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Eligible Participants, Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,634

4,274

3,899

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.23

$5.20

$4

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)

'

'

'

$5.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.12

$5.20

$4

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

'

'

'

39,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'2 years 200 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Stock Options Exercised (in Dollars)

'

'

'

2,793,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

'

'

'

1,700,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation (in Dollars)

'

'

'

$10,890,000

$5,732,000

$1,890,000

'

'

'

'

'

$0

$0

$98,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Average exercise price

Note_8_Stockholders_Equity_Det1

Note 8 - Stockholders' Equity (Details) - Option Valuation Assumptions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Stock Option [Member]	'	'	'
Note 8 - Stockholders' Equity (Details) - Option Valuation Assumptions [Line Items]	'	'	'
Expected term	'6 years	'5 years 186 days	'5 years
Risk-free interest rate	1.50%	0.80%	1.60%
Volatility	105.00%	106.00%	106.00%
Employee Stock Purchase Plan [Member]	'	'	'
Note 8 - Stockholders' Equity (Details) - Option Valuation Assumptions [Line Items]	'	'	'
Expected term	'178 days	'178 days	'6 months
Risk-free interest rate	0.80%	0.20%	0.80%
Volatility	212.00%	0.80%	142.00%

Note_8_Stockholders_Equity_Det2

Note 8 - Stockholders' Equity (Details) - Stock-based Compensation Expense (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 8 - Stockholders' Equity (Details) - Stock-based Compensation Expense [Line Items]	'	'	'
Share-based compensation expense	$10,890	$5,732	$1,890
Impact on basic and diluted net loss per common share (in Dollars per share)	$0.67	$0.47	$0.31
Research and Development Expense [Member]	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock-based Compensation Expense [Line Items]	'	'	'
Share-based compensation expense	2,562	1,585	819
General and Administrative Expense [Member]	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock-based Compensation Expense [Line Items]	'	'	'
Share-based compensation expense	$8,328	$4,147	$1,071

Note_8_Stockholders_Equity_Det3

Note 8 - Stockholders' Equity (Details) - Option Summary (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Option Summary [Abstract]	'	'	'
Outstanding at beginning of year	4,323,874	2,505,283	160,833
Outstanding at beginning of year (in Dollars per share)	$8.46	$6.13	$29.83
Granted	4,256,971	1,874,246	2,403,495
Granted (in Dollars per share)	$8.08	$11.61	$5.19
Exercised	-537,029	'	'
Exercised (in Dollars per share)	$5.20	'	'
Expired or Forfeited	-1,688,135	-55,655	-59,045
Expired or Forfeited (in Dollars per share)	$9.45	$9.56	$32.53
Outstanding at end of year	6,355,681	4,323,874	2,505,283
Outstanding at end of year (in Dollars per share)	$8.22	$8.46	$6.13
Outstanding at end of year	'8 years 51 days	'	'
Outstanding at end of year (in Dollars)	$10,704,578	'	'
Options exercisable at year end	1,770,597	1,142,099	337,002
Options exercisable at year end (in Dollars per share)	$8.67	$7.98	$10.68
Options exercisable at year end	'5 years 43 days	'	'
Options exercisable at year end (in Dollars)	4,607,452	'	'
Options vested or expected to vest	6,292,296	4,283,344	2,471,725
Options vested or expected to vest (in Dollars per share)	$8.22	$8.45	$6.14
Options vested or expected to vest	'8 years 47 days	'	'
Options vested or expected to vest (in Dollars)	$10,614,670	'	'
Shares available for future grant at year end	1,797,694	1,018,766	2,213,155
Weighted-average fair value of stock options granted during the year (in Dollars per share)	$8.08	$11.61	$5.19

Note_8_Stockholders_Equity_Det4

Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Number Outstanding - Options Outstanding (in Shares)	6,355,681	4,323,874	2,505,283	160,833
Weight-average Remaining Contractual Life - Options Outstanding	'8 years 51 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$8.22	$8.46	$6.13	$29.83
$3.80 to $3.80 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$3.80	'	'	'
Upper Range of Exercise Price	$3.80	'	'	'
Number Outstanding - Options Outstanding (in Shares)	5,000	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'7 years 361 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$3.80	'	'	'
Number Exercisable - Options Exercisable (in Shares)	2,708	'	'	'
Weighted-average Exercise Price - Options Exercisable	$3.80	'	'	'
$5.20 to $5.20 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$5.20	'	'	'
Upper Range of Exercise Price	$5.20	'	'	'
Number Outstanding - Options Outstanding (in Shares)	1,072,887	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'4 years 7 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$5.20	'	'	'
Number Exercisable - Options Exercisable (in Shares)	997,934	'	'	'
Weighted-average Exercise Price - Options Exercisable	$5.20	'	'	'
$6.40 to $7.00 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$6.40	'	'	'
Upper Range of Exercise Price	$7	'	'	'
Number Outstanding - Options Outstanding (in Shares)	386,613	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'8 years 219 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$6.85	'	'	'
Number Exercisable - Options Exercisable (in Shares)	80,210	'	'	'
Weighted-average Exercise Price - Options Exercisable	$6.66	'	'	'
$7.20 to $7.20 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$7.20	'	'	'
Upper Range of Exercise Price	$7.20	'	'	'
Number Outstanding - Options Outstanding (in Shares)	3,190,240	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'9 years 124 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$7.20	'	'	'
Number Exercisable - Options Exercisable (in Shares)	41,012	'	'	'
Weighted-average Exercise Price - Options Exercisable	$7.20	'	'	'
$7.40 to $10.60 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$7.40	'	'	'
Upper Range of Exercise Price	$10.60	'	'	'
Number Outstanding - Options Outstanding (in Shares)	852,372	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'9 years 138 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$9.89	'	'	'
Number Exercisable - Options Exercisable (in Shares)	105,881	'	'	'
Weighted-average Exercise Price - Options Exercisable	$10.57	'	'	'
$11.00 to $15.00 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$11	'	'	'
Upper Range of Exercise Price	$15	'	'	'
Number Outstanding - Options Outstanding (in Shares)	730,285	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'7 years 197 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$13.15	'	'	'
Number Exercisable - Options Exercisable (in Shares)	499,642	'	'	'
Weighted-average Exercise Price - Options Exercisable	$12.79	'	'	'
$15.40 to $130.40 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$15.40	'	'	'
Upper Range of Exercise Price	$130.40	'	'	'
Number Outstanding - Options Outstanding (in Shares)	117,598	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'6 years 160 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$24.14	'	'	'
Number Exercisable - Options Exercisable (in Shares)	42,524	'	'	'
Weighted-average Exercise Price - Options Exercisable	$39.54	'	'	'
$139.20 to $139.20 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$139.20	'	'	'
Upper Range of Exercise Price	$139.20	'	'	'
Number Outstanding - Options Outstanding (in Shares)	125	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'1 year 29 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$139.20	'	'	'
Number Exercisable - Options Exercisable (in Shares)	125	'	'	'
Weighted-average Exercise Price - Options Exercisable	$139.20	'	'	'
$196.00 to $196.00 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$196	'	'	'
Upper Range of Exercise Price	$196	'	'	'
Number Outstanding - Options Outstanding (in Shares)	436	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'14 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$196	'	'	'
Number Exercisable - Options Exercisable (in Shares)	436	'	'	'
Weighted-average Exercise Price - Options Exercisable	$196	'	'	'
$235.12 to $235.12 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$235.12	'	'	'
Upper Range of Exercise Price	$235.12	'	'	'
Number Outstanding - Options Outstanding (in Shares)	125	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'146 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$235.12	'	'	'
Number Exercisable - Options Exercisable (in Shares)	125	'	'	'
Weighted-average Exercise Price - Options Exercisable	$235.12	'	'	'
$3.80 to $235.12 [Member]	'	'	'	'
Note 8 - Stockholders' Equity (Details) - Stock Options Outstanding [Line Items]	'	'	'	'
Lower Range of Exercise Price	$3.80	'	'	'
Upper Range of Exercise Price	$235.12	'	'	'
Number Outstanding - Options Outstanding (in Shares)	6,355,681	'	'	'
Weight-average Remaining Contractual Life - Options Outstanding	'8 years 51 days	'	'	'
Weight-average Exercise Price - Options Outstanding	$8.22	'	'	'
Number Exercisable - Options Exercisable (in Shares)	1,770,597	'	'	'
Weighted-average Exercise Price - Options Exercisable	$8.67	'	'	'

Note_8_Stockholders_Equity_Det5

Note 8 - Stockholders' Equity (Details) - Warrants Outstanding (USD $)	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'
Number of Shares Exercisable	3,968,864
Exercise Price (in Dollars per Share)	$4.35	[1]
Issued to private placement investors in October 2009 [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares Exercisable	198,864
Exercise Price (in Dollars per Share)	$17.60
Issued to private placement investors in July 2011 [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares Exercisable	3,750,000
Exercise Price (in Dollars per Share)	$3.60
Other [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Shares Exercisable	20,000
Exercise Price (in Dollars per Share)	$13.80
[1]	Average exercise price

Note_8_Stockholders_Equity_Det6

Note 8 - Stockholders' Equity (Details) - Common Shares Reserved	Dec. 31, 2013
Note 8 - Stockholders' Equity (Details) - Common Shares Reserved [Line Items]	'
Common stock reserved for future issuance	22,023,232
Issuance Upon Exercise of Outstanding Stock Options [Member]	'
Note 8 - Stockholders' Equity (Details) - Common Shares Reserved [Line Items]	'
Common stock reserved for future issuance	6,355,681
Employee Stock Option [Member]	'
Note 8 - Stockholders' Equity (Details) - Common Shares Reserved [Line Items]	'
Common stock reserved for future issuance	1,797,694
Employee Stock Purchase Plan [Member]	'
Note 8 - Stockholders' Equity (Details) - Common Shares Reserved [Line Items]	'
Common stock reserved for future issuance	16,651
Issuance of Common Stock Related to Convertible Notes [Member]	'
Note 8 - Stockholders' Equity (Details) - Common Shares Reserved [Line Items]	'
Common stock reserved for future issuance	9,884,342	[1]
Issuance Upon Exercise of Warrants [Member]	'
Note 8 - Stockholders' Equity (Details) - Common Shares Reserved [Line Items]	'
Common stock reserved for future issuance	3,968,864
[1]	Assumes all interest payments are paid-in-kind through the maturity date.

Note_9_Net_Loss_Per_Share_Deta

Note 9 - Net Loss Per Share (Details) - Outstanding Potentially Dilutive Options, Warrants and Convertible Notes	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Equity Option [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities	6,356	4,324	2,505
Warrant [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities	3,969	4,219	4,206
Convertible Debt Securities [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive securities	6,291	5,927	1,967

Note_10_Discontinued_Operation2

Note 10 - Discontinued Operations (Details) (USD $)	12 Months Ended			24 Months Ended		84 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2007
Discontinued Operations and Disposal Groups [Abstract]	'	'	'	'	'	'
Liabilities for Guarantees on Long-Duration Contracts, Benefits Paid	'	'	'	'	'	$944,000
Increase (Decrease) in Other Accrued Liabilities	1,100,000	'	'	'	'	'
Disposal Group, Including Discontinued Operation, Revenue	$0	'	'	$0	$0	'
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share (in Dollars per share)	$0	$0.09	($0.06)	'	'	'

Note_10_Discontinued_Operation3

Note 10 - Discontinued Operations (Details) - Income (Loss) from Discontinued Operations (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Income (Loss) from Discontinued Operations [Abstract]	'	'
Change in estimates for guarantees	$1,082	($379)

Note_11_Defined_Contribution_P1

Note 11 - Defined Contribution Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation and Retirement Disclosure [Abstract]	'	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%	50.00%	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%	3.00%	3.00%
Defined Contribution Plan Employer Matching Contribution Amount	$7,650	$7,500	$7,350
Defined Benefit Plan, Contributions by Employer	134,000	71,000	46,000
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0	'	'

Note_12_Income_Taxes_Details

Note 12 - Income Taxes (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	$22	$8.90	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%	34.00%
Internal Revenue Service (IRS) [Member] | Subject To Limitations [Member]	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Operating Loss Carryforwards	75	'	'
Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Tax Credit Carryforward, Amount	2.2	'	'
Internal Revenue Service (IRS) [Member]	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Operating Loss Carryforwards	80.1	'	'
State and Local Jurisdiction [Member] | Subject To Limitations [Member]	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Operating Loss Carryforwards	74	'	'
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Tax Credit Carryforward, Amount	3.9	'	'
State and Local Jurisdiction [Member]	'	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'	'
Operating Loss Carryforwards	$79.10	'	'

Note_12_Income_Taxes_Details_C

Note 12 - Income Taxes (Details) - Components of Defered Tax Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Components of Defered Tax Assets [Abstract]	'	'	'
Net operating loss carryforwards	$31,834	$13,900	$6,700
Research credits	4,792	2,300	2,100
Stock compensation expense	4,124	2,600	600
Other	487	400	900
Total deferred tax assets	41,237	19,200	10,300
Valuation allowance	-41,237	-19,200	-10,300
Net deferred tax assets	$0	$0	$0

Note_12_Income_Taxes_Details_P

Note 12 - Income Taxes (Details) - Provisions (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Provisions [Abstract]	'	'	'
Tax benefit computed at 34%	($18,796)	($7,937)	($4,017)
Stock compensation expense	513	176	148
Other	300	210	70
NOL not benefitted	17,983	7,551	3,799
Tax Provision (Benefit)	$0	$0	$0

Note_12_Income_Taxes_Details_P1

Note 12 - Income Taxes (Details) - Provisions (Parentheticals)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Provisions [Abstract]	'	'	'
Federal statutory tax rate	34.00%	34.00%	34.00%

Note_12_Income_Taxes_Details_R

Note 12 - Income Taxes (Details) - Reconciliation of Unrecognized Tax Benefits (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits [Abstract]	'	'	'
At the beginning of the period	$120	$120	$120
Gross increases b tax positions in the current period	0	0	0
Gross decreases b tax positions in the current period	0	0	0
At the end of the period	$120	$120	$120

Note_13_Significant_Agreements1

Note 13 - Significant Agreements (Details) (Merial Limited [Member], Development Services [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2011
Merial Limited [Member] | Development Services [Member]	'
Note 13 - Significant Agreements (Details) [Line Items]	'
Revenues	$0.60

Note_14_Quarterly_Results_of_O2

Note 14 - Quarterly Results of Operations (Unaudited) (Details) - Quarterly Results of 2013 Operations (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Results of 2013 Operations [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	$0	$0	$0	$0	$0	$0	$0	$0	'	'	$646
Operating expenses	13,832	12,664	15,209	12,752	8,628	6,054	4,380	4,769	54,457	23,831	11,708
Interest and other expense, net	-212	-209	-204	-201	-197	-195	-146	-61	-826	-599	-373
Net loss	($14,044)	($12,873)	($15,413)	($12,953)	($7,737)	($6,121)	($4,569)	($4,921)	($55,283)	($23,348)	($11,814)
Net loss (in Dollars per share)	($0.75)	($0.84)	($1.01)	($0.85)	($0.51)	($0.45)	($0.46)	($0.49)	($3.42)	($1.91)	($1.96)

Note_14_Quarterly_Results_of_O3

Note 14 - Quarterly Results of Operations (Unaudited) (Details) - Quarterly Results of 2012 Operations (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Results of 2012 Operations [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	$0	$0	$0	$0	$0	$0	$0	$0	'	'	$646
Operating expenses	13,832	12,664	15,209	12,752	8,628	6,054	4,380	4,769	54,457	23,831	11,708
Interest and other expense, net	-212	-209	-204	-201	-197	-195	-146	-61	-826	-599	-373
Loss from continuing operations	'	'	'	'	-8,825	-6,249	-4,526	-4,830	-55,283	-24,430	-11,435
Discontinued operations	'	'	'	'	1,088	128	-43	-91	'	'	'
Net loss	($14,044)	($12,873)	($15,413)	($12,953)	($7,737)	($6,121)	($4,569)	($4,921)	($55,283)	($23,348)	($11,814)
Loss from continuing operations (in Dollars per share)	'	'	'	'	($0.58)	($0.46)	($0.45)	($0.48)	($3.42)	($2)	($1.90)
Net loss (in Dollars per share)	($0.75)	($0.84)	($1.01)	($0.85)	($0.51)	($0.45)	($0.46)	($0.49)	($3.42)	($1.91)	($1.96)

Note_15_Subsequent_Event_Detai

Note 15 - Subsequent Event (Details)	Dec. 31, 2013	Dec. 31, 2012	Jan. 13, 2014	Jan. 13, 2014	Jan. 13, 2014
			Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			Scenario, Previously Reported [Member]	Common Stock [Member]
Note 15 - Subsequent Event (Details) [Line Items]	'	'	'	'	'
Stockholders' Equity Note, Stock Split, Conversion Ratio	'	'	'	20	'
Common Stock, Shares Authorized	75,000,000	75,000,000	1,500,000,000	'	75,000,000